Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

Preoperative Considerations for Cutaneous Surgery: Selecting Patients, Managing Medications, Antibiotics, and Anesthesia

Description

The speaker reviews key preoperative considerations for cutaneous surgery, emphasizing that surgery is not always the best option. Decisions should account for goals of care, cancer type and risk, patient preferences, comorbidities, and expected outcomes, especially in older adults. For low-risk superficial or nodular basal cell carcinoma, SCC in situ, small low-risk squamous cell carcinomas on the trunk and extremities, and some moderately atypical nevi with positive margins, non-surgical approaches or observation may be reasonable. Evidence cited suggests low-risk BCCs often grow slowly, deep shave biopsy can sometimes fully remove presumed superficial/nodular BCC without recurrence, and topical or destructive treatments such as 5-fluorouracil with calcipotriene, curettage, or ED&C can achieve good cure rates and cosmesis. For SCC in situ and selected low-risk SCCs, especially in poor surgical candidates, topical or destructive therapy and intralesional 5-FU may be effective. For atypical nevi, consensus guidance and follow-up studies support observation of some moderately atypical lesions with positive margins. If surgery is needed but the site is hard to find, a Woods lamp can help identify biopsy sites. On anticoagulants, most should be continued, with exceptions such as heparin products and special caution with Bruton kinase inhibitors; abrutinib is highlighted as a drug on which surgery should be avoided or delayed due to significant bleeding risk. Regarding prophylactic antibiotics, the speaker argues they should be used rarely because dermatologic surgery infection rates are generally low and antibiotics often do not reduce infections even in higher-risk sites like the lower leg; they remain important mainly for infective endocarditis or joint prophylaxis in specific mucosal or infected-skin cases. For anesthesia, the speaker recommends combining short- and long-acting agents, using lidocaine with epinephrine for rapid onset and bupivacaine/ropivacaine for longer relief, along with techniques to reduce pain such as warming the solution, injecting slowly, using numb skin or nerve blocks, buffering, vibration devices, dose calculators, and careful evaluation of claimed lidocaine allergy. Finally, the talk stresses monitoring vitals to distinguish vasovagal, epinephrine, and anaphylactic reactions, and advises clinicians to listen to their clinical intuition or “the voice” to avoid mistakes.

View more

Conclusions

  • For many low-risk cutaneous lesions, especially superficial or nodular BCC on the trunk/extremities and low-risk SCC in situ or small well-differentiated SCC, non-surgical or less invasive management can be appropriate when paired with careful patient selection.
  • Watchful waiting or biopsy-based removal strategies can be safe for selected basal cell carcinomas, with low-risk tumors growing slowly and deep shave removal often achieving clear margins without recurrence in follow-up.
  • Topical or destructive therapies such as 5-fluorouracil plus calcipotriene and ED&C can provide high cure rates for selected superficial keratinocyte carcinomas while avoiding surgery.
  • Moderately atypical nevi with positive margins can often be observed rather than re-excised, because long-term studies found no melanomas at the biopsy site and very low rates of repigmentation.
  • If surgery is needed but the biopsy site is hard to find, a Woods lamp can help localize residual pigment and blood products for more accurate site identification.
  • Most anticoagulants should be continued for dermatologic surgery, but ibrutinib is a notable exception because it carries a clinically important bleeding risk and should generally be held perioperatively.
  • Routine preoperative antibiotics should be used very sparingly in dermatologic surgery because infection rates are usually low and prophylaxis does not reliably prevent infections, even on the lower leg.
  • Antibiotic prophylaxis is mainly reserved for clearly higher-risk scenarios such as oral mucosal or infected skin procedures and certain endocarditis or joint-infection risk situations.
  • Good local anesthesia practice relies on using both short-acting and long-acting agents, minimizing injection pain, and respecting dose limits.
  • Patient comfort during dermatologic surgery can be improved by warming anesthetic, injecting slowly, using nerve blocks or vibratory distraction, and considering dilution strategies when appropriate.
  • Reported lidocaine allergy should be questioned carefully, and uncertain cases are better referred for allergy evaluation than assumed to be true allergy.
  • Listening to clinical intuition or the ‘voice’ of experience is presented as an important final safeguard against missing atypical or deeper pathology before operating.
  • Geriatric dermatologic surgery part II: Peri- and intraoperative considerations in the geriatric dermatologic surgery patient. Journal of the American Academy of Dermatology.#10.1016/j.jaad.2024.02.060
  • Evaluation of Watchful Waiting and Tumor Behavior in Patients With Basal Cell Carcinoma: An Observational Cohort Study of 280 Basal Cell Carcinomas in 89 Patients. JAMA Dermatology.#10.1001/jamadermatol.2021.3020
  • Deep Shave Removal of Suspected Basal Cell Carcinoma: A Prospective Study.#10.1016/j.jaad.2018.05.427
  • Combined topical 5-fluorouracil and calcipotriene treatment for skin cancer/field therapy (article excerpt cited on slide).
  • Recurrence rates after curettage alone for basal cell carcinoma (article excerpt cited on slide).
  • Oncologic Outcomes for Squamous Cell Carcinoma In Situ With a Clinically Resolved Biopsy Site Managed by Watchful Waiting. Dermatologic Surgery.#10.1097/dss.0000000000004202
  • Electrodesiccation and Curettage for Squamous Cell Carcinoma in Situ: The Effect of Anatomic Location on Local Recurrence. Dermatologic Surgery.#10.1097/dss.0000000000003855
  • Oncologic outcomes for invasive squamous cell carcinoma with a clinically resolved biopsy site managed by watchful waiting: A retrospective cohort study. Journal of the American Academy of Dermatology.#10.1016/j.jaad.2024.11.067
  • Addressing the knowledge gap in clinical recommendations for management and complete excision of clinically atypical nevi/dysplastic nevi: Pigmented Lesion Subcommittee consensus statement. JAMA Dermatology.#10.1001/jamadermatol.2014.2694
  • Risk of Subsequent Cutaneous Melanoma in Moderately Dysplastic Nevi Excisionally Biopsied but With Positive Histologic Margins.#10.3410/f.734212704.793554282
  • Part 1: Management of antithrombotic medications in dermatologic surgery. Journal of the American Academy of Dermatology.#10.1016/j.jaad.2024.01.096
  • Association of Ibrutinib Treatment With Bleeding Complications in Cutaneous Surgery. JAMA Dermatology.#10.1001/jamadermatol.2017.1877
  • Perioperative Bleeding Associated With Ibrutinib in Dermatologic Surgery: A Case-Control Study.#10.1097/dss.0000000000003590
  • Use of Antibiotics for Dermatologic Procedures From 2008 to 2016. JAMA Dermatology. 2019 Apr 1;155(4):465-470.#10.1001/jamadermatol.2019.0152
  • Emergent crisis of antibiotic resistance: A silent pandemic threat to 21st century. Microbial Pathogenesis.#10.1016/j.micpath.2022.105923
  • 2008 Journal of the American Academy of Dermatology advisory statement on antibiotic prophylaxis in dermatologic surgery.#10.1016/j.jaad.2008.04.031
  • A Simple Elastomer-Pad Vibratory Dampener to Maximize Pain Control of Injections in Patient's Undergoing Dermatological Surgery. Dermatol Surg. 2016 Jun;42(6):788-90. doi:10.1097/DSS.0000000000000718.#10.1097/DSS.0000000000000718
  • Efficacy of 0.25% Lidocaine Versus 0.5% Lidocaine in Dermatologic Surgery: A Double-Blind, Randomized Controlled Trial. Dermatologic Surgery.#10.1097/dss.0000000000004319